Moderna and Merck reported data regarding their cutting-edge mRNA-based skin cancer regimen that includes the former’s cancer vaccine, MRNA-4157. This mRNA-based skin cancer regimen represents one of ...

CDC notes that the BA.2.86 (Pirola) variant may be more likely to break through existing immunity from previous vaccination or infection, highlighting the need for vaccination with an updated COVID-19 ...

Moderna MRNA and Merck MRK announced new data for individualized neoantigen therapy mRNA-4157 on Monday at the annual meeting of the American Society of Clinical Oncology that was consistent with our ...

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...

Moderna MRNA announced positive results from the pivotal phase III NextCOVE study evaluating mRNA-1283, its next-generation refrigerator-stable COVID-19 vaccine, in individuals aged 12 years and older ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the afternoon session after the broader biotech sector ...

CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the ...

No sooner did Moderna (MRNA) and Merck & Co. (MRK) announce additional positive data for their cancer vaccine candidate, a messenger RNA (mRNA)-based individualized neoantigen therapy (INT), than ...

Moderna and Merck & Co. have presented positive mid-stage data at the American Association for Cancer Research (AACR) Annual Meeting 2023 for the combination of their personalized cancer vaccine (PCV) ...

New data indicate Moderna’s Covid bivalent booster may be more effective against currently circulating Omicron variants of the virus than its original vaccine, the company said Monday. Like data ...